Proximo Medical Named Commercialization Partner for BIOTRONIK’s PVI portfolio in Select U.S. Markets

This fall, Proximo Medical announced that it is the commercial partner for BIOTRONIK, Inc.’s peripheral vascular intervention (PVI) platform in select U.S. markets. BIOTRONIK’s comprehensive portfolio includes versatile stent systems, balloon catheters and sheaths to address the growing peripheral artery disease (PAD) market.

Biotronik logo

“By partnering BIOTRONIK’s solutions and innovations with Proximo, we accelerate our ability to help physicians deliver improved outcomes to patients,” states Ryan Walters, President, BIOTRONIK, Inc.  “We know millions of Americans suffer from peripheral artery disease and this partnership will help ensure this patient population has access to safe and effective treatment options.”

A key opinion leader offers his perspective on BIONTRONIK solutions:

“I was an investigator in the trial of the BIOTRONIK Pulsar stent,” states Craig Walker, MD, President and Medical Director, Cardiovascular Institute of the South; Clinical Professor of Medicine, Tulane University and Louisiana State University Medical Schools; and Chairman, New Cardiovascular Horizons. “I was impressed that this stent, which has a 4F delivery system, was easy to deploy accurately and had good clinical patency. I think this will be very helpful particularly in cases where standard 5F or 6F sheaths may be occlusive.”

BIOTRONIK, who’s partnered with hospitals and health systems for more than 50 years, is headquartered in Berlin, Germany, and represented in over 100 countries.

Learn more about the partnership HERE.